Peptide Reference
HGH Fragment 176-191
Human Growth Hormone Fragment 176-191
A modified form of amino acids 176-191 of human growth hormone. Designed to provide fat-burning benefits of HGH without the growth effects.
Status
research
Category
weight loss
Typical cost
$50-100/vial (5mg)
Mechanism
Mimics the fat-burning portion of HGH without affecting blood sugar or tissue growth. Stimulates lipolysis and inhibits lipogenesis.
Potential benefits
- Targeted fat loss
- No blood sugar effects
- No growth effects
- Improved metabolism
- No IGF-1 elevation
- No organ growth
Reported side effects
- Injection site reactions
- Limited human data
- Banned in sports
- Cancer concerns theoretical
Common dosing references
subcutaneous
250-500mcg · Daily
4-8 weeks
subcutaneous
250-500mcg · Daily or 2x daily
4-8 weeks
Research notes
HGH fragment fat burning
2004
Demonstrated lipolytic effects without growth-promoting activity
HGH fragment lipolysis
2004
Demonstrated lipolytic effects without growth-promoting activity in research
Beta-3 receptor mechanism
2008
Fat loss occurs through beta-3-adrenergic receptor pathway
Regulatory and sourcing notes
Research chemical only. Not FDA-approved. Banned by WADA.
Research peptide. Similar to AOD-9604. Banned by anti-doping agencies.
Find peptide-aware clinics
Use location pages to compare clinics with peptide therapy signals and verify clinical oversight before treatment.